Shares of ImmuPharma plc (LON:IMM – Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of GBX 4.07 and traded as low as GBX 3.60. ImmuPharma shares last traded at GBX 3.85, with a volume of 2,063,786 shares trading hands.
ImmuPharma Trading Up 4.1%
The firm has a 50 day simple moving average of GBX 3.63 and a 200 day simple moving average of GBX 4.07. The firm has a market capitalization of £24.07 million, a PE ratio of -4.64 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. Research analysts forecast that ImmuPharma plc will post -339.00 earnings per share for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
